TRAIL R3/TNFRSF10C PE-conjugated Antibody | R&D Systems FAB6302P product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

antibody

product name :

TRAIL R3/TNFRSF10C PE-conjugated Antibody

catalog :

FAB6302P

quantity :

100 Tests

price :

376 USD

clonality :

monoclonal

host :

mouse

conjugate :

clone name :

90906

reactivity :

human

application :

flow cytometry

citations: 15

Published Application/Species/Sample/Dilution	Reference
flow cytometry; human; fig st1	Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
flow cytometry; human	Kim S, Woo J, Jeong C, Ryu C, Jang J, Jeun S. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med. 2014;3:172-82 pubmed publisher
flow cytometry; human	Kalb M, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-?-mediated antitumor reactivity. J Immunol. 2012;188:1583-91 pubmed publisher
flow cytometry; human	Secchiero P, Melloni E, Corallini F, Beltrami A, Alviano F, Milani D, et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells. 2008;26:2955-63 pubmed publisher
flow cytometry; human	Wu C, Kao C, Safa A. TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5. Hum Gene Ther. 2008;19:731-43 pubmed publisher
flow cytometry; human	Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy P, Lampertico P, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007;204:667-80 pubmed
	Jo E, Lee Y, Lee H, Park J, Park H, Choi Y, et al. Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells. BMC Cancer. 2019;19:496 pubmed publisher
	Shlyakhtina Y, Pavet V, Gronemeyer H. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells. Cell Death Dis. 2017;8:e3025 pubmed publisher
	Jaworska D, Szliszka E. Targeting Apoptotic Activity Against Prostate Cancer Stem Cells. Int J Mol Sci. 2017;18: pubmed publisher
	Singh H, Otano I, Rombouts K, Singh K, Peppa D, Gill U, et al. TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Sci Rep. 2017;7:5514 pubmed publisher
	Chen J, Bozza W, Di X, Zhang Y, Hallett W, Zhang B. H-Ras regulation of TRAIL death receptor mediated apoptosis. Oncotarget. 2014;5:5125-37 pubmed
	Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, et al. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res. 2014;34:729-34 pubmed
	Trebing J, El Mesery M, Schafer V, Weisenberger D, Siegmund D, Silence K, et al. CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants. Cell Death Dis. 2014;5:e1035 pubmed publisher
	Gojo I, Tan M, Fang H, Sadowska M, Lapidus R, Baer M, et al. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res. 2013;19:1838-51 pubmed publisher
	Kim S, Lim J, Park S, Jeong C, Oh J, Jeong M, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 2008;68:9614-23 pubmed publisher

product information

brand :

R&D Systems

master code :

FAB6302P

SKU :

FAB6302P

product name :

TRAIL R3/TNFRSF10C PE-conjugated Antibody

description :

The Human TRAIL R3/TNFRSF10C PE-conjugated Antibody from R&D Systems is a mouse monoclonal antibody to TRAILR3/TNFRSF10C. This antibody reacts with human. The Human TRAIL R3/TNFRSF10C PE-conjugated Antibody has been validated for the following applications: Flow Cytometry.

target :

TRAIL R3/TNFRSF10C

category :

Primary Antibodies

sizes available :

100 Tests

buffer :

Supplied in a saline solution containing BSA and Sodium Azide.

clonality :

Monoclonal

clone :

90906

conjugate :

Phycoerythrin

host :

Mouse

immunogen :

Mouse myeloma cell line NS0-derived recombinant human TRAIL R3/TNFRSF10C, Met1-Ala221, Accession # O14798

isotype :

IgG1

purity :

Protein A or G purified from hybridoma culture supernatant

species :

Human

specificity :

Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots

gene symbol :

TNFRSF10C

accessionNumbers :

O14798

applications :

Flow Cytometry

USD :

376 USD

alt names :

Antagonist decoy receptor for TRAIL/Apo-2L, CD263, CD263 antigen, cytotoxic TRAIL receptor-3, DcR1, DCR1MGC149502, Decoy receptor 1, Decoy TRAIL receptor without death domain, LITMGC149501, Lymphocyte inhibitor of TRAIL, TNFRSF10C, TRAIL receptor 3, TRAIL receptor without an intracellular domain, TRAILR3, TRAIL-R3, TRAILR3TNF-related apoptosis-inducing ligand receptor 3, TRIDDCR1-TNFR, tumor necrosis factor receptor superfamily member 10C, tumor necrosis factor receptor superfamily, member 10c, decoy without anintracellular domain

storage :

Store the unopened product at 2 - 8° C. Do not use past expiration date. Protect from light.